226 related articles for article (PubMed ID: 11408334)
1. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
Barkhof F; van Waesberghe JH; Filippi M; Yousry T; Miller DH; Hahn D; Thompson AJ; Kappos L; Brex P; Pozzilli C; Polman CH;
Brain; 2001 Jul; 124(Pt 7):1396-402. PubMed ID: 11408334
[TBL] [Abstract][Full Text] [Related]
2. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
Molyneux PD; Kappos L; Polman C; Pozzilli C; Barkhof F; Filippi M; Yousry T; Hahn D; Wagner K; Ghazi M; Beckmann K; Dahlke F; Losseff N; Barker GJ; Thompson AJ; Miller DH
Brain; 2000 Nov; 123 ( Pt 11)():2256-63. PubMed ID: 11050025
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
4. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.
Brex PA; Molyneux PD; Smiddy P; Barkhof F; Filippi M; Yousry TA; Hahn D; Rolland Y; Salonen O; Pozzilli C; Polman CH; Thompson AJ; Kappos L; Miller DH;
Neurology; 2001 Dec; 57(12):2185-90. PubMed ID: 11756595
[TBL] [Abstract][Full Text] [Related]
5. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
6. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.
Rieckmann P; Kruse N; Nagelkerken L; Beckmann K; Miller D; Polman C; Dahlke F; Toyka KV; Hartung HP; Stürzebecher S
J Neurol; 2005 May; 252(5):526-33. PubMed ID: 15895275
[TBL] [Abstract][Full Text] [Related]
7. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
Kappos L; Polman C; Pozzilli C; Thompson A; Beckmann K; Dahlke F;
Neurology; 2001 Dec; 57(11):1969-75. PubMed ID: 11739811
[TBL] [Abstract][Full Text] [Related]
8. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Waubant E; Goodkin D; Bostrom A; Bacchetti P; Hietpas J; Lindberg R; Leppert D
Neurology; 2003 Jan; 60(1):52-7. PubMed ID: 12525717
[TBL] [Abstract][Full Text] [Related]
9. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
Inglese M; van Waesberghe JH; Rovaris M; Beckmann K; Barkhof F; Hahn D; Kappos L; Miller DH; Polman C; Pozzilli C; Thompson AJ; Yousry TA; Wagner K; Comi G; Filippi M
Neurology; 2003 Mar; 60(5):853-60. PubMed ID: 12629246
[TBL] [Abstract][Full Text] [Related]
10. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
[TBL] [Abstract][Full Text] [Related]
11. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.
Jeffery DR; Chepuri N; Durden D; Burdette J
Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510
[TBL] [Abstract][Full Text] [Related]
12. MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b.
Sormani MP; Bruzzi P; Beckmann K; Wagner K; Miller DH; Kappos L; Filippi M;
Neurology; 2003 May; 60(9):1462-6. PubMed ID: 12743232
[TBL] [Abstract][Full Text] [Related]
13. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
[TBL] [Abstract][Full Text] [Related]
14. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
15. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
Molyneux PD; Barker GJ; Barkhof F; Beckmann K; Dahlke F; Filippi M; Ghazi M; Hahn D; MacManus D; Polman C; Pozzilli C; Kappos L; Thompson AJ; Wagner K; Yousry T; Miller DH;
Neurology; 2001 Dec; 57(12):2191-7. PubMed ID: 11756596
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.
Simon JH; Lull J; Jacobs LD; Rudick RA; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Sheeder J; Miller D; McCabe K; Serra A; Campion MK; Fischer JS; Goodkin DE; Simonian N; Lajaunie M; Wende K; Martens-Davidson A; Kinkel RP; Munschauer FE
Neurology; 2000 Jul; 55(2):185-92. PubMed ID: 10908888
[TBL] [Abstract][Full Text] [Related]
17. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
18. Interferon β for secondary progressive multiple sclerosis: a systematic review.
La Mantia L; Vacchi L; Rovaris M; Di Pietrantonj C; Ebers G; Fredrikson S; Filippini G
J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):420-6. PubMed ID: 22952326
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
20. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.
Zhao GJ; Koopmans RA; Li DK; Bedell L; Paty DW
Neurology; 2000 Jan; 54(1):200-6. PubMed ID: 10636148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
